Professor Marek Lubusky, MD, PhD, MHAProfessor Marek Lubusky, MD, PhD, MHA

Pilka R., Míčková I., Lubušký M. , Dušková M., Říčánková M., Kudela M. Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer. Čes. Gynek., 2008, 73 (4), s. 222-227.

ABSTRACT

ABSTRACT

Objective: To assess the immunohistochemical expression of p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors in endometrial cancer patients.

Design: Experimental study.

Setting: Department of Obstetrics and Gynecology, Institute of Human Genetics, Department of Pathology, Palacky University Medical School and University Hospital, Olomouc.

Methods: We studied 103 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, cerb-2, Ki-67, estrogen and progesterone receptor antigens were investigated by an immunohistochemical method. We evaluated the correlations among the immunohistochemical staining assessed by histoscore, and the age, grading, depth of invasion, stage of the neoplasia and extrauterine disease.

Results: Mean age was 67 years (range 35-90). p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors were positive in 49 (48%), 81 (79%). 18 (17%), 99 (96%), 73 (70%) and 87 (84%) patients respectively. There was no clear association between immunohistochemical parameters and the age of patients. p53 and Ki-67 overexpression was found to be related to poor grade of differentiation, deeper myometrial invasion, advanced stage of neoplasia and extrauterine spread of disease. Immunostaining for bcl-2 correlated inversely with FIGO stage, while c-erb-2 was overexpressed in tumors with deeper myometrial invasion. Estrogen and progesterone receptor positive tumors showed astatistically significant association with clinicopathological parameters of better clinical outcome.

Conclusion: The overexpression of p53 and Ki-67 seems to indicate more malignant phenotype, while bcl-2 and c-erb-2 may have alimited role in the identification of high-risk tumors.

Key words: endometrial cancer, immunohistochemistry, prognostic factors.



ULTRAZVUK V PORODNICTVÍ A GYNEKOLOGII | portál Sekce ultrazvukové diagnostiky ČGPS ČLS JEP Moravská konference fetomaternální medicíny Olomouc
Fulltext search
 

Contact

Professor Marek Lubusky, MD, PhD, MHA

THE FETAL MEDICINE CENTRE
Department of Obstetrics and Gynecology
Palacky University Olomouc, Faculty of Medicine and Dentistry
University Hospital Olomouc
I. P. Pavlova 6, 77520 Olomouc, Czech Republic
Tel: +420 585 852 785
Mobil: +420 606 220 644
E-mail: marek@lubusky.com
Web: www.lubusky.com


Contact form
NAME
E-MAIL
MESSAGE
 
© ESMEDIA a.s.